Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Zai Lab, MacroGenics enters into collaboration to develop, commercialize » 07:39
06/16/21
06/16
07:39
06/16/21
07:39
ZLAB

Zai Lab

$165.89 /

-4.16 (-2.45%)

, MGNX

MacroGenics

$20.50 /

-0.29 (-1.39%)

Zai Lab (ZLAB) and…

Zai Lab (ZLAB) and MacroGenics (MGNX) announced that the companies have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. The first collaboration program covers a lead research molecule that incorporates MacroGenics' DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors. The next-generation CD3 component of the DART bispecific molecule has been designed to minimize cytokine-release syndrome while maintaining anti-tumor cytolytic activity. The second collaboration program will cover a target to be designated by MacroGenics. For both molecules, Zai receives commercial rights in Greater China, Japan, and Korea and MacroGenics receives commercial rights in all other territories. For the lead molecule, Zai Lab receives an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules. For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies. Under the terms of the agreement, MacroGenics receives initial consideration from Zai Lab of $55M, including an upfront payment of $25M and an equity investment of $30M in MacroGenics' common stock at $31.30 per share. In addition, MacroGenics is eligible to receive up to $1.4B in potential development, regulatory and commercial milestone payments for the four programs. If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Lab's territories.

ShowHide Related Items >><<
ZLAB Zai Lab
$165.89 /

-4.16 (-2.45%)

MGNX MacroGenics
$20.50 /

-0.29 (-1.39%)

ZLAB Zai Lab
$165.89 /

-4.16 (-2.45%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
MGNX MacroGenics
$20.50 /

-0.29 (-1.39%)

06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
04/30/21 H.C. Wainwright
MacroGenics price target raised to $41 from $36 at H.C. Wainwright
04/26/21 Credit Suisse
MacroGenics assumed with an Outperform at Credit Suisse
03/12/21 Barclays
MacroGenics upgraded to Overweight from Underweight at Barclays
ZLAB Zai Lab
$165.89 /

-4.16 (-2.45%)

MGNX MacroGenics
$20.50 /

-0.29 (-1.39%)

  • 21
    Apr
ZLAB Zai Lab
$165.89 /

-4.16 (-2.45%)

MGNX MacroGenics
$20.50 /

-0.29 (-1.39%)

Over a week ago
Hot Stocks
Mirati Therapeutics, Zai Lab enter collaboration for adagrasib in Greater China » 07:52
06/01/21
06/01
07:52
06/01/21
07:52
MRTX

Mirati Therapeutics

$158.06 /

+5.31 (+3.48%)

, ZLAB

Zai Lab

$177.62 /

+8.66 (+5.13%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China. Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Mirati will receive a $65M upfront payment, with the potential to receive up to an additional $273M in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China.

ShowHide Related Items >><<
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

05/17/21
Fly Intel: Top five analyst downgrades
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/10/21 Jefferies
Jefferies upgrades Mirati Therapeutics to Buy after 35% pullback
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

  • 21
    Apr
  • 28
    Oct
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

Hot Stocks
Mirati and Zai Lab enter into collaboration and license agreement for adagrasib » 07:32
06/01/21
06/01
07:32
06/01/21
07:32
MRTX

Mirati Therapeutics

$158.06 /

+5.31 (+3.48%)

, ZLAB

Zai Lab

$177.62 /

+8.66 (+5.13%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China. Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Mirati will receive a $65M upfront payment, with the potential to receive up to an additional $273 million in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China.

ShowHide Related Items >><<
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

05/17/21
Fly Intel: Top five analyst downgrades
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/10/21 Jefferies
Jefferies upgrades Mirati Therapeutics to Buy after 35% pullback
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

MRTX Mirati Therapeutics
$158.06 /

+5.31 (+3.48%)

  • 21
    Apr
  • 28
    Oct
ZLAB Zai Lab
$177.62 /

+8.66 (+5.13%)

Hot Stocks
Zai Lab announces first patient treated in China in Phase 2 TRIDENT-1 study » 07:33
05/28/21
05/28
07:33
05/28/21
07:33
ZLAB

Zai Lab

$168.96 /

+4.42 (+2.69%)

, TPTX

Turning Point Therapeutics

$67.82 /

-0.74 (-1.08%)

Zai Lab (ZLAB) announced…

Zai Lab (ZLAB) announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics (TPTX) and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China. The registrational Phase 2 portion of TRIDENT-1 study is a multi-center trial evaluating repotrectinib for the treatment of patients with ROS1+ advanced NSCLC as well as patients with NTRK+ advanced solid tumors. The primary endpoint of the Phase 2 portion of the trial is overall response rate assessed by Blinded Independent Central Review. Secondary endpoints include duration of response, progression free survival, safety and tolerability. Zai Lab is enrolling patients in Greater China, while Turning Point is enrolling patients in other regions of the world. Turning Point disclosed on May 5 that the FDA recently guided that a type B meeting should be requested to discuss topline BICR results of cohort 1 of the registrational TRIDENT-1 study when responders have been followed for at least six months past onset of response. Turning Point believes it may be in a position to discuss the topline results from patients treated within EXP-1 with the FDA during the first quarter of 2022.

ShowHide Related Items >><<
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

  • 21
    Apr
  • 27
    Oct
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

Hot Stocks
Zai Lab announces first patient treated in Greater China in METIS Phase 3 trial » 09:25
05/24/21
05/24
09:25
05/24/21
09:25
ZLAB

Zai Lab

$164.51 /

+2.05 (+1.26%)

, NVCR

Novocure

$181.17 /

-1.13 (-0.62%)

Zai Lab Limited (ZLAB)…

Zai Lab Limited (ZLAB) announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Zai's partner NovoCure Limited (NVCR) to study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer. The METIS trial is a pivotal, randomized, controlled Phase 3 trial designed to test the efficacy and safety of TTFields, generated by a medical device, the NovoTTF-100M System, in patients with 1-10 newly diagnosed brain metastasis from NSCLC. TTFields are administered to patients concomitantly with the best standard of care treatments that would normally be used to treat lung cancer. The trial is expected to enroll 270 patients randomized 1:1 to receive, following radiosurgery, either TTFields at a frequency of 150kHz plus supportive care or supportive care alone. The primary endpoint is time to first cerebral progression. Secondary endpoints include, among others, time to neurocognitive failure, overall survival, and radiological response rate.

ShowHide Related Items >><<
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
NVCR Novocure
$181.17 /

-1.13 (-0.62%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

  • 21
    Apr
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

Over a month ago
Earnings
Zai Lab reports Q1 EPS ($2.64), two est. ($1.58) » 07:44
05/10/21
05/10
07:44
05/10/21
07:44
ZLAB

Zai Lab

$157.90 /

+2.705 (+1.74%)

Reports Q1 revenue…

Reports Q1 revenue $20.1M, two est. $29.89M. "Zai Lab continued to execute well in all aspects of the business during the first quarter," said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. "We entered into several strategic collaborations to further strengthen our gastric and lung cancer disease strongholds; significantly bolstered our autoimmune franchise with an exclusive agreement with argenx for efgartigimod, a pipeline-in-a-product opportunity; advanced numerous clinical programs toward key data readouts; gained approval of QINLOCK by the National Medical Products Administration, our third innovative oncology product approval in the last 15 months in China and the first commercial product in what we expect to become a world-class gastric cancer franchise; and generated solid revenue growth, in part from increased volume of ZEJULA driven by its recent inclusion on the National Reimbursement Drug List. In addition, we recently received encouraging news on several key assets from our partners. The Biologics License Application filing of efgartigimod in generalized myasthenia gravis was accepted by the U.S. Food and Drug Administration. The Phase 3 pivotal LUNAR trial of Tumor Treating Fields in non-small cell lung cancer was recommended to continue with reduced sample size based on an accelerated interim analysis. Bemarituzumab was granted Breakthrough Therapy Designation by the FDA as first-line treatment for gastric cancer patients who overexpress FGFR2b. With the completion of our recent global public offering with gross proceeds of nearly $860 million, we significantly strengthened our capital position. This new capital will allow us to accelerate our growth by entering into additional strategic partnerships, advancing our clinical development pipeline, and scaling our commercial and R&D organizations to drive strong revenue growth and enhance our global pipeline. We remain on target to advance all stages of our product pipeline throughout 2021. We continue to expect approval of Nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections by the NMPA. We plan to file margetuximab for Her2-positive breast cancer, Tumor Treating Fields for mesothelioma and ZEJULA for late-line ovarian cancer in China. We are engaging with the NMPA on the regulatory filing strategy for efgartigimod in gMG in China. And we anticipate numerous data readouts, including for Tumor Treating Fields in liver cancer and ovarian cancer, for QINLOCK in second-line GIST, for margetuximab in gastric cancer, for CLN-081 in NSCLC and for TPX-0022 in NSCLC and gastric cancer. n our mission to address serious unmet medical needs for patients in China and around the world, we believe that we have built a sustainable platform that we can leverage," Dr. Du concluded. "Our team continues to deliver on our aggressive growth objectives. I believe that the future of Zai Lab has never been brighter."

ShowHide Related Items >><<
ZLAB Zai Lab
$157.90 /

+2.705 (+1.74%)

ZLAB Zai Lab
$157.90 /

+2.705 (+1.74%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$157.90 /

+2.705 (+1.74%)

  • 21
    Apr
ZLAB Zai Lab
$157.90 /

+2.705 (+1.74%)

Syndicate
Zai Lab 4.78M share Secondary priced at $150.00 » 19:42
04/20/21
04/20
19:42
04/20/21
19:42
ZLAB

Zai Lab

$150.96 /

-13.5 (-8.21%)

The deal priced below the…

The deal priced below the last closing price of $150.77. JPMorgan, Goldman Sachs, Jefferies, Citi, SVB Leerink and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ZLAB Zai Lab
$150.96 /

-13.5 (-8.21%)

ZLAB Zai Lab
$150.96 /

-13.5 (-8.21%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$150.96 /

-13.5 (-8.21%)

  • 21
    Apr
ZLAB Zai Lab
$150.96 /

-13.5 (-8.21%)

On The Fly
Fly Intel: After-Hours Movers » 18:30
04/19/21
04/19
18:30
04/19/21
18:30
IBM

IBM

$133.40 /

-0.195 (-0.15%)

, HXL

Hexcel

$57.25 /

-0.07 (-0.12%)

, WTFC

Wintrust Financial

$78.36 /

+0.07 (+0.09%)

, CCK

Crown Holdings

$108.73 /

-0.42 (-0.38%)

, UAL

United Airlines

$55.01 /

-0.84 (-1.50%)

, STLD

Steel Dynamics

$51.35 /

-0.13 (-0.25%)

, FUTU

Futu Holdings

$177.83 /

+25.01 (+16.37%)

, ZLAB

Zai Lab

$164.34 /

+0.15 (+0.09%)

Check out this evening's…

ShowHide Related Items >><<
ZLAB Zai Lab
$164.34 /

+0.15 (+0.09%)

WTFC Wintrust Financial
$78.36 /

+0.07 (+0.09%)

UAL United Airlines
$55.01 /

-0.84 (-1.50%)

STLD Steel Dynamics
$51.35 /

-0.13 (-0.25%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

HXL Hexcel
$57.25 /

-0.07 (-0.12%)

FUTU Futu Holdings
$177.83 /

+25.01 (+16.37%)

CCK Crown Holdings
$108.73 /

-0.42 (-0.38%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

04/08/21 Morgan Stanley
IBM price target raised to $150 from $140 at Morgan Stanley
03/24/21 Evercore ISI
Intel price target raised to $75 from $68 at Evercore ISI
03/23/21 KeyBanc
Box price target raised to $27 from $22 at KeyBanc
03/12/21 JMP Securities
Domo price target raised to $89 from $80 at JMP Securities
HXL Hexcel
$57.25 /

-0.07 (-0.12%)

04/15/21 Wells Fargo
Hexcel price target raised to $60 from $49 at Wells Fargo
03/26/21
Fly Intel: Top five analyst downgrades
03/26/21 Goldman Sachs
Hexcel downgraded to Sell from Neutral at Goldman Sachs
03/16/21 Barclays
Hexcel upgraded to Equal Weight from Underweight at Barclays
WTFC Wintrust Financial
$78.36 /

+0.07 (+0.09%)

04/09/21 Jefferies
Wintrust Financial price target raised to $85 from $75 at Jefferies
03/16/21 Raymond James
Wintrust Financial price target raised to $96 from $78 at Raymond James
02/01/21 Janney Montgomery Scott
Janney Montgomery Scott upgrades Wintrust to Buy, says pullback 'overdone'
02/01/21 Janney Montgomery Scott
Wintrust Financial upgraded to Buy from Neutral at Janney Montgomery Scott
CCK Crown Holdings
$108.73 /

-0.42 (-0.38%)

04/15/21 Jefferies
Crown Holdings price target raised to $134 from $123 at Jefferies
04/15/21 Jefferies
Ball Corp. price target raised to $96 from $93 at Jefferies
04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
UAL United Airlines
$55.01 /

-0.84 (-1.50%)

04/16/21
Fly Intel: Top five analyst upgrades
04/16/21 Argus
United Airlines upgraded to Buy on capacity and cost plans at Argus
04/16/21 Argus
United Airlines upgraded to Buy from Hold at Argus
04/15/21 Barclays
United Airlines price target raised to $62 from $44 at Barclays
STLD Steel Dynamics
$51.35 /

-0.13 (-0.25%)

04/09/21 Goldman Sachs
Steel Dynamics initiated with a Buy at Goldman Sachs
03/18/21 BMO Capital
Steel Dynamics price target raised to $52 from $46 at BMO Capital
02/03/21
Fly Intel: Top five analyst upgrades
02/03/21 Credit Suisse
Steel Dynamics upgraded to Outperform from Neutral at Credit Suisse
FUTU Futu Holdings
$177.83 /

+25.01 (+16.37%)

03/17/21 Citi
Futu Holdings price target lowered to $230.30 from $246.50 at Citi
02/26/21 Citi
Futu Holdings price target raised to $246.50 from $119.70 at Citi
02/22/21 86 Research
Futu Holdings downgraded to Hold from Buy at 86 Research
02/16/21 Morgan Stanley
Futu Holdings initiated with an Overweight at Morgan Stanley
ZLAB Zai Lab
$164.34 /

+0.15 (+0.09%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$164.34 /

+0.15 (+0.09%)

WTFC Wintrust Financial
$78.36 /

+0.07 (+0.09%)

UAL United Airlines
$55.01 /

-0.84 (-1.50%)

STLD Steel Dynamics
$51.35 /

-0.13 (-0.25%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

HXL Hexcel
$57.25 /

-0.07 (-0.12%)

CCK Crown Holdings
$108.73 /

-0.42 (-0.38%)

  • 21
    Apr
  • 21
    Apr
  • 19
    Aug
  • 22
    Apr
WTFC Wintrust Financial
$78.36 /

+0.07 (+0.09%)

UAL United Airlines
$55.01 /

-0.84 (-1.50%)

STLD Steel Dynamics
$51.35 /

-0.13 (-0.25%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

HXL Hexcel
$57.25 /

-0.07 (-0.12%)

FUTU Futu Holdings
$177.83 /

+25.01 (+16.37%)

CCK Crown Holdings
$108.73 /

-0.42 (-0.38%)

ZLAB Zai Lab
$164.34 /

+0.15 (+0.09%)

UAL United Airlines
$55.01 /

-0.84 (-1.50%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

HXL Hexcel
$57.25 /

-0.07 (-0.12%)

FUTU Futu Holdings
$177.83 /

+25.01 (+16.37%)

CCK Crown Holdings
$108.73 /

-0.42 (-0.38%)

UAL United Airlines
$55.01 /

-0.84 (-1.50%)

STLD Steel Dynamics
$51.35 /

-0.13 (-0.25%)

IBM IBM
$133.40 /

-0.195 (-0.15%)

FUTU Futu Holdings
$177.83 /

+25.01 (+16.37%)

Syndicate
Zai Lab files to sell $750M in ADSs » 16:09
04/19/21
04/19
16:09
04/19/21
16:09
ZLAB

Zai Lab

$163.97 /

-0.22 (-0.13%)

J.P. Morgan Securities…

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC, Citigroup Global Markets Inc., SVB Leerink LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the ADS offering. J.P. Morgan Securities plc, Goldman Sachs (Asia) L.L.C., Jefferies Hong Kong Limited, Citigroup Global Markets Limited and Guggenheim Securities, LLC are acting as joint book-running managers in respect of any ordinary shares issued to investors electing to receive ordinary shares in lieu of ADSs.

ShowHide Related Items >><<
ZLAB Zai Lab
$163.97 /

-0.22 (-0.13%)

ZLAB Zai Lab
$163.97 /

-0.22 (-0.13%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
ZLAB Zai Lab
$163.97 /

-0.22 (-0.13%)

ZLAB Zai Lab
$163.97 /

-0.22 (-0.13%)

Recommendations
Zai Lab price target raised to $192 from $183 at SVB Leerink » 14:23
04/14/21
04/14
14:23
04/14/21
14:23
ZLAB

Zai Lab

$163.50 /

+2.2 (+1.36%)

SVB Leerink analyst…

SVB Leerink analyst Jonathan Chang raised the firm's price target on Zai Lab to $192 from $183 and keeps an Outperform rating on the shares following what he calls the "encouraging" Optune update from partner Novocure (NVCR) in the LUNAR phase 3 non-small cell lung cancer trial. Chang is updating his model to reflect a faster timeline as well as increasing his view on the probability of success for the Optune lung cancer opportunity to 90% from 65%.

ShowHide Related Items >><<
ZLAB Zai Lab
$163.50 /

+2.2 (+1.36%)

ZLAB Zai Lab
$163.50 /

+2.2 (+1.36%)

04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
01/15/21 Citi
Citi boosts Zai Lab target to $216, adds to U.S. Focus List
ZLAB Zai Lab
$163.50 /

+2.2 (+1.36%)

ZLAB Zai Lab
$163.50 /

+2.2 (+1.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.